Characteristics of the 54 HIV-infected subjects
| Characteristic . | LTS . | Progressors . | AIDS . |
|---|---|---|---|
| Patients, n | 23 | 12 | 19 |
| Age, median (range) | 47 (35-59) | 47 (38-57) | 44.5 (34-61) |
| Ethnicity | |||
| Caucasian, n | 22 (96%) | 11 (92%) | 15 (79%) |
| Other, n | 1 (4%) | 1 (8%) | 4 (21%) |
| Medical history | |||
| Recurrent HSV, n | 2 (87%) | 3 (25%) | 3 (16%) |
| Chronic HBV, n | 0 | 3 (25%) | 1 (5%) |
| Chronic HCV, n | 0 | 2 (17%) | 2 (10%) |
| Risk group | |||
| Homosexual | 23 (100%) | 12 (100%) | 16 (85%) |
| Bisexual | 0 | 0 | 2 (10%) |
| IV drug use | 0 | 0 | 1 (5%) |
| Years from seroconversion | 14 (1-19) | 14 (2-20) | 10 (1-18) |
| Therapy | |||
| Antiretroviral | 0 | 9 (75%) | 12 (63%) |
| Acyclovir | 1 (4%) | 2 (17%) | 4 (21%) |
| Corticosteroids | 0 | 0 | 3 (16%) |
| IFN-α | 0 | 1 (8%) | 2 (10%) |
| Characteristic . | LTS . | Progressors . | AIDS . |
|---|---|---|---|
| Patients, n | 23 | 12 | 19 |
| Age, median (range) | 47 (35-59) | 47 (38-57) | 44.5 (34-61) |
| Ethnicity | |||
| Caucasian, n | 22 (96%) | 11 (92%) | 15 (79%) |
| Other, n | 1 (4%) | 1 (8%) | 4 (21%) |
| Medical history | |||
| Recurrent HSV, n | 2 (87%) | 3 (25%) | 3 (16%) |
| Chronic HBV, n | 0 | 3 (25%) | 1 (5%) |
| Chronic HCV, n | 0 | 2 (17%) | 2 (10%) |
| Risk group | |||
| Homosexual | 23 (100%) | 12 (100%) | 16 (85%) |
| Bisexual | 0 | 0 | 2 (10%) |
| IV drug use | 0 | 0 | 1 (5%) |
| Years from seroconversion | 14 (1-19) | 14 (2-20) | 10 (1-18) |
| Therapy | |||
| Antiretroviral | 0 | 9 (75%) | 12 (63%) |
| Acyclovir | 1 (4%) | 2 (17%) | 4 (21%) |
| Corticosteroids | 0 | 0 | 3 (16%) |
| IFN-α | 0 | 1 (8%) | 2 (10%) |
LTS, long-term survivors; HSV, herpes simplex virus; HBV, hepatitis B virus; HCV, hepatitis C virus; IV, intravenous; IFN, interferon.